Larry Robbins's MYGN Position Overview
Larry Robbins (via Glenview Capital Management, LLC) currently holds 4.59 M shares of Myriad Genetics, Inc. (MYGN) worth $28.21 M, representing 0.57% of the portfolio. First purchased in 2019-Q3, this long-term strategic position has been held for 26 quarters.
Based on 13F filings, Larry Robbins has maintained a strategic position in MYGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 2.9 M shares. Largest reduction occurred in Q3 2024, reducing 2.49 M shares.
Analysis based on 13F filings available since 2013 Q2
Larry Robbins's Myriad Genetics (MYGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Myriad Genetics (MYGN) Trades by Larry Robbins
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2025 | +687,857 | Add 17.64% | 4.59 M | $5.31 |
| Q1 2025 | -257,774 | Reduce 6.20% | 3.9 M | $8.87 |
| Q4 2024 | +2.9 M | Add 229.55% | 4.16 M | $13.71 |
| Q3 2024 | -2.49 M | Reduce 66.35% | 1.26 M | $27.39 |
| Q2 2024 | -1.2 M | Reduce 24.18% | 3.75 M | $24.46 |
| Q1 2024 | -340,387 | Reduce 6.44% | 4.94 M | $21.32 |
| Q4 2023 | +1.5 M | Add 39.64% | 5.28 M | $19.14 |
| Q3 2023 | +39,094 | Add 1.04% | 3.78 M | $16.04 |
| Q2 2023 | -450,224 | Reduce 10.73% | 3.74 M | $23.18 |
| Q1 2023 | +1.1 M | Add 35.42% | 4.2 M | $23.23 |
| Q4 2022 | +1.64 M | Add 111.96% | 3.1 M | $14.51 |
| Q3 2022 | -235,307 | Reduce 13.87% | 1.46 M | $19.08 |
| Q2 2022 | -40,218 | Reduce 2.32% | 1.7 M | $18.17 |
| Q1 2022 | +57,262 | Add 3.41% | 1.74 M | $25.20 |
| Q4 2021 | -555,421 | Reduce 24.85% | 1.68 M | $27.60 |
| Q3 2021 | -240,912 | Reduce 9.73% | 2.24 M | $32.29 |
| Q2 2021 | -93,353 | Reduce 3.63% | 2.48 M | $30.58 |
| Q1 2021 | -1.11 M | Reduce 30.23% | 2.57 M | $30.45 |
| Q4 2020 | +924,698 | Add 33.53% | 3.68 M | $19.77 |
| Q3 2020 | +947,266 | Add 52.31% | 2.76 M | $13.04 |
| Q2 2020 | +271,196 | Add 17.62% | 1.81 M | $11.34 |
| Q1 2020 | -1.91 M | Reduce 55.31% | 1.54 M | $14.31 |
| Q4 2019 | -238,511 | Reduce 6.48% | 3.44 M | $27.23 |
| Q3 2019 | +3.68 M | New Buy | 3.68 M | $28.63 |
Larry Robbins's Myriad Genetics Investment FAQs
Larry Robbins first purchased Myriad Genetics, Inc. (MYGN) in Q3 2019, acquiring 3,683,306 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Larry Robbins has held Myriad Genetics, Inc. (MYGN) for 26 quarters since Q3 2019.
Larry Robbins's largest addition to Myriad Genetics, Inc. (MYGN) was in Q3 2019, adding 3,683,306 shares worth $105.45 M.
According to the latest 13F filing for Q4 2025, Larry Robbins's firm, Glenview Capital Management, LLC, owns 4,587,407 shares of Myriad Genetics, Inc. (MYGN), valued at approximately $28.21 M.
As of the Q4 2025 filing, Myriad Genetics, Inc. (MYGN) represents approximately 0.57% of Larry Robbins's publicly disclosed stock portfolio, making it one of their key holdings.
Larry Robbins's peak holding in Myriad Genetics, Inc. (MYGN) was 5,283,982 shares, as reported at the end of Q4 2023.